4.6 Review

Next-Generation Service Delivery: A Scoping Review of Patient Outcomes Associated with Alternative Models of Genetic Counseling and Genetic Testing for Hereditary Cancer

期刊

CANCERS
卷 10, 期 11, 页码 -

出版社

MDPI
DOI: 10.3390/cancers10110435

关键词

BRCA; genetic counseling; genetic testing; hereditary cancer; genetic service delivery; patient outcomes

类别

向作者/读者索取更多资源

The combination of increased referral for genetic testing and the current shortage of genetic counselors has necessitated the development and implementation of alternative models of genetic counseling and testing for hereditary cancer assessment. The purpose of this scoping review is to provide an overview of the patient outcomes that are associated with alternative models of genetic testing and genetic counseling for hereditary cancer, including germline-only and tumor testing models. Seven databases were searched, selecting studies that were: (1) full-text articles published >= 2007 or conference abstracts published >= 2015, and (2) assessing patient outcomes of an alternative model of genetic counseling or testing. A total of 79 publications were included for review and synthesis. Data-charting was completed using a data-charting form that was developed by the study team for this review. Seven alternative models were identified, including four models that involved a genetic counselor: telephone, telegenic, group, and embedded genetic counseling models; and three models that did not: mainstreaming, direct, and tumor-first genetic testing models. Overall, these models may be an acceptable alternative to traditional models on knowledge, patient satisfaction, psychosocial measures, and the uptake of genetic testing; however, particular populations may be better served by traditional in-person genetic counseling. As precision medicine initiatives continue to advance, institutions should consider the implementation of new models of genetic service delivery, utilizing a model that will best serve the needs of their unique patient populations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Correction Oncology

Survival from breast cancer in women with a BRCA2 mutation by treatment (vol 124, pg 1524, 2021)

D. Gareth Evans, Kelly-Anne Phillips, Roger L. Milne, Robert Fruscio, Cezary Cybulski, Jacek Gronwald, Jan Lubinski, Tomasz Huzarski, Zerin Hyder, Claire Forde, Kelly Metcalfe, Leigha Senter, Jeffrey Weitzel, Nadine Tung, Dana Zakalik, Maria Ekholm, Ping Sun, Steven A. Narod

BRITISH JOURNAL OF CANCER (2023)

Article Oncology

The risks of cancer in older women with BRCA pathogenic variants: How far have we come?

Kelly A. Metcalfe, Jacek Gronwald, Nadine M. Tung, Jeanna M. McCuaig, Andrea Eisen, Christine Elser, William D. Foulkes, Susan L. Neuhausen, Leigha Senter, Pal Moller, Louise Bordeleau, Robert Fruscio, Lea Velsher, Dana Zakalik, Olufunmilayo Olopade, Charis Eng, Tuya Pal, Carey A. Cullinane, Fergus J. Couch, Joanne Kotsopoulos, Ping Sun, Jan Lubinski, Steven A. Narod

Summary: The study aimed to estimate the cumulative risks of all cancers in women aged 50 to 75 with a BRCA1 or BRCA2 gene mutation. The results showed that women with BRCA1 or BRCA2 mutations have a high risk of cancer, particularly breast and ovarian cancer, between the ages of 50 and 75. Therefore, appropriate counseling should be provided to these women.

CANCER (2023)

Article Endocrinology & Metabolism

FLCN-Driven Functional Adrenal Cortical Carcinoma with High Mitotic Tumor Grade: Extending the Endocrine Manifestations of Birt-Hogg-Dube Syndrome

Renee Hofstedter, Maria Carolina Sanabria-Salas, Maria Di Jiang, Shereen Ezzat, Ozgur Mete, Raymond H. Kim

Summary: Adrenal cortical carcinoma is a rare and aggressive malignancy that originates from steroidogenic cells of the adrenal gland. It is often sporadic but can be associated with inherited tumor syndromes. There have been very few reports of adrenal cortical neoplasia in patients with BHD syndrome. We present a case of adrenal cortical carcinoma in a 50-year-old female with a germline pathogenic variant in the FLCN gene. Genetic testing revealed the same variant in the tumor, suggesting its contribution to the pathogenesis of adrenal cortical carcinoma. This case expands our understanding of BHD syndrome and highlights the importance of genetic testing for FLCN in patients with adrenal cortical carcinomas.

ENDOCRINE PATHOLOGY (2023)

Article Genetics & Heredity

SCIP: software for efficient clinical interpretation of copy number variants detected by whole-genome sequencing

Qiliang Ding, Cherith Somerville, Roozbeh Manshaei, Brett Trost, Miriam S. Reuter, Kelsey Kalbfleisch, Kaitlin Stanley, John B. A. Okello, S. Mohsen Hosseini, Eriskay Liston, Meredith Curtis, Mehdi Zarrei, Edward J. Higginbotham, Ada J. S. Chan, Worrawat Engchuan, Bhooma Thiruvahindrapuram, Stephen W. Scherer, Raymond H. Kim, Rebekah K. Jobling

Summary: This study introduces SCIP, a software package that enables efficient and accurate clinical interpretation of CNVs, facilitating improved genetic diagnoses.

HUMAN GENETICS (2023)

Article Genetics & Heredity

Patient-reported outcomes associated with reflex BRCA1/2 tumor and subsequent germline panel genetic testing for high-grade serous ovarian cancer

Jeanna M. McCuaig, Tracy L. Stockley, Sarah E. Ferguson, Danielle Vicus, Sarah Brennenstuhl, Karen Ott, Raymond H. Kim, Kelly A. Metcalfe

Summary: This study evaluated the psychological outcomes following tumor and germline genetic testing in individuals with HGSOC. The results showed a significant decrease in genetic testing-related distress following receipt of germline results with genetic counseling. Most individuals were satisfied with this model of care.

JOURNAL OF GENETIC COUNSELING (2023)

Article Genetics & Heredity

Oncologist-led germline genetic testing for uveal melanoma

Brittany Gillies, Hatem Krema, Anning Chao, Leonardo Lando, Kirsten M. Farncombe, Marcus Butler, Filiberto Altomare, Raymond H. Kim

Summary: This study reports the results of genetic testing and phenotype analysis of a cohort of unselected uveal melanoma patients. The collaboration between the medical genetics clinic and oncologists in a mainstreaming model plays a central role in facilitating genetic testing and counseling for patients with hereditary cancer predisposition.

OPHTHALMIC GENETICS (2023)

Article Genetics & Heredity

Current and new frontiers in hereditary cancer surveillance: Opportunities for liquid biopsy

Kirsten M. Farncombe, Derek Wong, Maia L. Norman, Leslie E. Oldfield, Julia A. Sobotka, Mark Basik, Yvonne Bombard, Victoria Carile, Lesa Dawson, William D. Foulkes, David Malkin, Aly Karsan, Patricia Parkin, Lynette S. Penney, Aaron Pollett, Kasmintan A. Schrader, Trevor J. Pugh, Raymond H. Kim

Summary: At least 5% of cancer diagnoses in individuals with hereditary cancer syndrome (HCS) are attributed to genetic variants. Cell-free DNA sequencing has shown potential as a non-invasive strategy for monitoring cancer in HCS individuals. The CHARM Consortium in Canada aims to assess the clinical validity of cfDNA in HCS and explore opportunities for its incorporation into surveillance protocols.

AMERICAN JOURNAL OF HUMAN GENETICS (2023)

Article Oncology

Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation

Joanne Kotsopoulos, Jacek Gronwald, Tomasz Huzarski, Amber Aeilts, Susan Randall Armel, Beth Karlan, Christian Singer, Andrea Eisen, Nadine Tung, Olufunmilayo Olopade, Louise Bordeleau, Charis Eng, William Foulkes, Susan Neuhausen, Carey Cullinane, Tuya Pal, Robert Fruscio, Jan Lubinski, Kelly Metcalfe, Ping Sun, Steven Narod

Summary: The use of selective estrogen receptor modulators like tamoxifen or raloxifene may be effective in reducing the risk of breast cancer in women with BRCA mutations. However, further research is needed to confirm these findings.

BREAST CANCER RESEARCH AND TREATMENT (2023)

Letter Clinical Neurology

Congenital Myopathy Due to Pathogenic Missense Variant in the MYBPC1 Gene

Vinaya Bhandari, Raymond Kim, Hanna Faghfoury, Josh Silver, Raymond H. Chan, Qiliang Ding, Marci L. B. Schwartz, Vera Bril

CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2023)

Article Genetics & Heredity

Next generation of free? Points to consider when navigating sponsored genetic testing

Kirsten Bartels, Samantha Afonso, Lindsay Brown, Claudia Carriles, Raymond Kim, Joanna Lazier, Saadet Mercimek-Andrews, Tanya N. Nelson, Ian Stedman, Emily Thain, Rachel Vanneste, Lauren Chad

Summary: Sponsored genetic testing provides a simplified access to genetic testing for patients and healthcare practitioners, but it raises ethical and legal considerations as well as differences in publicly funded healthcare systems. Further research and dialogue are needed to provide comprehensive considerations.

JOURNAL OF MEDICAL GENETICS (2023)

Article Oncology

Theory-based behavior change intervention to increase uptake of risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 pathogenic variant: The PREVENT randomized controlled trial

Kelly A. Metcalfe, Tuya Pal, Steven A. Narod, Susan Armel, Salma Shickh, Kathleen Buckley, Scott T. Walters, Sarah Brennenstuhl, Anita Y. Kinney

Summary: This study aimed to evaluate the effect of a theory-based behavioral intervention delivered by genetic counselors on the uptake of risk-reducing salpingo-oophorectomy (RRSO) by women with BRCA1 or BRCA2 pathogenic variants (PVs) compared to usual care. Findings showed that the intervention significantly reduced decisional conflict and increased knowledge at one-year, and resulted in a higher proportion of RRSO at two years compared to usual care.

CANCER MEDICINE (2023)

Meeting Abstract Oncology

Comparison of thirty-year population-based incidence rates of invasive lobular vs ductal vs mixed breast carcinoma in Ontario, Canada

David Wai Lim, Vasily Giannakeas, Steven Narod, Kelly A. Metcalfe

CANCER RESEARCH (2023)

Meeting Abstract Oncology

Population-based survival outcomes of pure vs mixed invasive lobular breast carcinoma in Ontario, Canada

David Lim, Vasily Giannakeas, Steven Narod, Kelly Metcalfe

CANCER RESEARCH (2023)

Meeting Abstract Oncology

Prevalence of Pathogenic Variants in Cancer Predisposition Genes in Women with Young Onset Breast Cancer

Kelly Metcalfe, May Lynn Quan, Steven Narod, Ellen Warner, Christine Friedenreich, Nancy Baxter, Aletta J. Poll, Mohammad Akbari

CANCER RESEARCH (2023)

Article Biochemistry & Molecular Biology

I just wanted more: Hereditary cancer syndromes patients' perspectives on the utility of circulating tumour DNA testing for cancer screening

Ella Adi-Wauran, Marc Clausen, Salma Shickh, Anna R. Gagliardi, Avram Denburg, Leslie E. Oldfield, Jordan Sam, Emma Reble, Suvetha Krishnapillai, Dean A. Regier, Nancy N. Baxter, Lesa Dawson, Lynette S. Penney, William Foulkes, Mark Basik, Sophie Sun, Kasmintan A. Schrader, Aly Karsan, Aaron Pollett, Trevor J. Pugh, Raymond H. Kim, Yvonne Bombard, Lesa Dawson, Krista Rideout, Stacy Whittle, Lynette S. Penney, Karin Wallace, Shelley M. MacDonald, Mark Basik, William Foulkes, Adriana Aguilar-Mahecha, Zoulikha Rezoug, Victoria Carile, Josiane Lafleur, Yvonne Bombard, Nancy N. Baxter, Irfan Dhalla, Brian Mckee, Nicole Mittmann, Monika Kastner, Michelle R. Jacobson, Marcus Q. Bernardini, Gabrielle E. V. Ene, Raymond H. Kim, Trevor J. Pugh, Leslie E. Oldfield, Kirsten M. Farncombe, Lillian Siu, Stephanie Lheureux, Sarah Ferguson, Christine Elser, Tulin Cil, Shelley Westergard, Emily Thain, Hal Berman, Wei Xu, Celeste Yu, Maia L. Norman, Clarissa F. Chan, Precious Uju, Phil Bedard, Blaise Clarke, Jeanna McCuaig, Aaron Pollett, Melyssa Aronson, Robert Gryfe, Seema Panchal, Carolyn Piccinin, Thomas Ward, Kara Semotiuk, Jordan Lerner-Ellis, Dean Regier, Aly Karsan, Kasmintan A. Schrader, Pardeep Kaurah, Sophie Sun, Sara Singh

Summary: This study explored patients' perspectives on the utility of circulating tumour DNA (ctDNA) in hereditary cancer syndromes (HCS). The participants expressed high levels of concern regarding cancer development, particularly for those without reliable screening options. They were enthusiastic about ctDNA's potential for comprehensive, predictive, and tailored cancer detection, while acknowledging its limitations. Overall, the participants believed that ctDNA could improve their care in HCS.

EUROPEAN JOURNAL OF HUMAN GENETICS (2023)

暂无数据